101. Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.
- Author
-
Gullbo J, Arsenau D, Grundmark B, Alvfors C, Larsson R, and Lindhagen E
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Doxorubicin chemistry, Doxorubicin pharmacokinetics, Drug Screening Assays, Antitumor, Drug Synergism, Ethanolamines chemistry, Ethanolamines pharmacokinetics, Humans, Micelles, Phosphotyrosine analogs & derivatives, Phosphotyrosine chemistry, Phosphotyrosine pharmacokinetics, Tumor Cells, Cultured drug effects, Tyrosine analogs & derivatives, Tyrosine pharmacology, Antineoplastic Agents pharmacology, Doxorubicin pharmacology, Ethanolamines pharmacology, Phosphotyrosine pharmacology
- Abstract
Background: Liposomal formulations of the anthracyclines are being developed to circumvent toxicity and prolong effect. The current study investigates the in vitro activity of a novel doxorubicin micelle formulation, containing a vehicle designed to release pharmacologically active subcomponents., Materials and Methods: The cytotoxicity of doxorubicin formulated in a vehicle containing C4 (N-docosahexaenoyl-O-phospho-2-aminoethanol) and C11 (N-all trans-retinoyl-O-phospho-L-tyrosine) was measured in a panel of human tumor cell lines, 19 primary cultures of human tumor cells and 5 lymphocyte preparations., Results and Conclusion: At the tested ratio between doxorubicin and C4/C11 (1:50), C4/C11 contributed significantly to the in vitro toxicity. However, the molar EC50-values were lower for doxorubicin than for C4/C11. Synergistic interactions between doxorubicin and C4/C11 were evident in a majority of the cell types studied. C4/C11 increased the cellular load of the fluorescent Pgp substrate calcein. To further investigate the possible benefits of the new formulation, in vivo studies are ongoing.
- Published
- 2002